Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma

Sally E. Trabucco1, Rachel M. Gerstein2, Andrew M. Evens3, James E. Bradner4, Leonard D. Shultz2, Dale L. Greiner6, and Hong Zhang1

Abstract

Purpose: Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) enter long-term remission after standard chemotherapy. Patients with DLBCL who do not respond to chemotherapy have few treatment options. There remains a critical need to identify effective and targeted therapeutics for DLBCL.

Experimental Design: Recent studies have highlighted the incidence of increased c-MYC protein in DLBCL and the correlation between high levels of c-MYC protein and poor survival prognosis of patients with DLBCL, suggesting that c-MYC is a compelling target for DLBCL therapy. The small molecule JQ1 suppresses c-MYC expression through inhibition of the bromodomain and extra-terminal (BET) family of bromodomain proteins. We investigated whether JQ1 can inhibit proliferation of DLBCL cells in culture and xenograft models in vivo.

Results: We show that JQ1 at nanomolar concentrations efficiently inhibited proliferation of human DLBCL cells in a dose-dependent manner regardless of their molecular subtypes, suggesting a broad effect of JQ1 in DLBCL. The initial G1 arrest induced by JQ1 treatment in DLBCL cells was followed by either apoptosis or senescence. The expression of c-MYC was suppressed as a result of JQ1 treatment from the natural, chromosomally translocated, or amplified loci. Furthermore, JQ1 treatment significantly suppressed growth of DLBCL cells engrafted in mice and improved survival of engrafted mice.

Conclusion: Our results demonstrate that inhibition of the BET family of bromodomain proteins by JQ1 has potential clinical use in the treatment of DLBCL. Clin Cancer Res 21(1): 113–22. ©2014 AACR.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non–Hodgkin lymphoma, accounting for 30% to 40% of all diagnoses (1). Approximately 50% of patients with DLBCL enter long-term remission after R-CHOP therapy, which includes a combination of chemotherapeutic agents (doxorubicin, cyclophosphamide, and vincristine), prednisone, and the anti-CD20 monoclonal antibody rituximab. The inclusion of rituximab, which ablates B cells, improves the cure rate of DLBCL by 10% to 15% (2), indicating the benefit of targeted therapeutics. However, patients who do not respond to R-CHOP therapy or relapse soon after treatment have poor prognosis (2), and outside of possible stem cell transplantation, are left with few treatment options (3). Furthermore, DLBCL occurs mostly in elderly patients, with an average age of mid-60s at diagnosis, who often have confounding factors diminishing their tolerance of chemotherapy and are often not able to tolerate intensive therapy such as transplantation. Thus, it is important to develop new targeted therapies to decrease relapse and increase the efficacy of current therapy.

DLBCL is heterogeneous with significant variations in morphology, clinical presentation, and response to treatment (4). Gene expression profiling identifies biologically and clinically distinct molecular subtypes of DLBCL: activated B-cell–like (ABC), germinal center B-cell–like (GCB), and primary mediastinal B-cell lymphoma (PMBL) (13–15). These subtypes differ in molecular features and cell of origin, each arising from distinct molecular processes that ultimately lead to neoplastic transformation. Chromosomal translocations of BCL2 or c-MYC and mutations in EZH2 are more common in the GCB subtype (6, 10–12), whereas alterations in BLIMP1/PRDM1 (13–15) and various mutations leading to activation of the NF-κB pathway (16–20) are associated with the ABC subtype. Common to both GCB and ABC subtypes are BCL6 translocations (21, 22) and mutations in CREBBP and EP300 (23). Additional recurrent mutations in DLBCL have been identified recently (23–27), although the functional consequence of these mutations in lymphomagenesis has not been studied experimentally. Once identified, these genetic alterations provide promising targets for developing new therapeutics. In particular, a number of reports recently have highlighted the incidence

1Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, Massachusetts. 2Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts. 3Division of Hematology and Oncology, Tufts Medical Center, Boston, Massachusetts. 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5The Jackson Laboratory, Bar Harbor, Maine. 6Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Corresponding Author: Hong Zhang, Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA 01655. Phone: 508-856-5423; Fax: 508-856-1033; E-mail: hong.zhang@umassmed.edu

do:10.1158/1078-0432.CCR-13-3346
©2014 American Association for Cancer Research.
Translational Relevance

JQ1 is a small-molecule inhibitor of the bromodomain and extra-terminal (BET) family of bromodomain proteins. Recent studies have found antiproliferative and proapoptotic effects of JQ1 in several types of malignancies. In our preclinical evaluation of JQ1 in treatment of human diffuse large B-cell lymphoma (DLBCL), we found that JQ1 has a broad antitumor activity in human DLBCL cells regardless of their molecular subtypes. JQ1 treatment resulted in either cell death or cell senescence in human DLBCL cells and led to suppression of c-MYC expression. We showed that JQ1 significantly suppressed growth of DLBCL cells engrafted in mice and improved survival of tumor-bearing mice, demonstrating a potential use of JQ1 in DLBCL treatment. We speculate that the addition of JQ1 as a component of salvage therapy or even potentially added to the standard R-CHOP therapy may result in the effective treatment of DLBCL.

of both c-MYC translocations (8.8%–11%) and increased protein levels of c-MYC (29%–31.8%) in DLBCL (28, 29). Moreover, high level of c-MYC protein is an adverse prognostic factor of DLBCL (28), suggesting that treatments targeting c-MYC may be beneficial clinically for patients with DLBCL.

JQ1 is a small-molecule inhibitor of the bromodomain and extra-terminal (BET) family of bromodomain proteins, with the highest affinity for BRD4 (30). BRD4 is a scaffolding factor that associates with acetylated chromatin to facilitate active transcription. JQ1 competitively interacts with BRD, thus preventing BRD4 from binding to chromatin (30). Lovén and colleagues found that BRD4 preferentially occupies enhancers and super-enhancers in cancer cells, thereby increasing expression of genes already selected for expression (31). They proposed that JQ1-mediated inhibition of BRD4 preferentially decreases expression of oncogenes which have been highly selected for in any specific cancer (31). A recent study revealed highly asymmetric loading of BRD4 at super-enhancers in DLBCL cells. These super-enhancers and genes that they regulate are particularly sensitive to JQ1 inhibition, explaining the selective effect of JQ1 on oncogenic and lineage-specific transcriptional circuits (32). One such example is the c-MYC oncogene, which has been shown in many hematopoietic malignancies to be necessary for response to JQ1 (33–37). This led us to hypothesize that JQ1 treatment in DLBCL cells would result in decreased cell proliferation and viability in a c-MYC–dependent manner. We show here that human DLBCL cells were sensitive to JQ1 treatment in culture. These cells underwent G1 cell-cycle arrest followed by either apoptosis or senescence. JQ1 treatment led to suppression of c-MYC expression, suggesting a c-MYC–dependent inhibition by JQ1. Furthermore, we found that JQ1 treatment significantly inhibited tumor growth and improved survival of mice with transplanted DLBCL cells in xenograft models.

Materials and Methods

Cell lines and cell culture

Human DLBCL cell lines OCI-Ly18, RC-K8, and SU-DHL-5 were provided by Dr. John Manis at Harvard Medical School (Boston, MA); HBL-1, HLY-1, and OCI-Ly8 were provided by Dr. Louis Staudt at National Cancer Institute (Bethesda, MD); and OCI-Ly3, OCI-Ly10, SU-DHL-4 and SU-DHL-6 were provided by Dr. Subbarao Bondada at University of Kentucky (Lexington, KY). These cells lines were not authenticated independently. DLBCL cells were maintained in RPMI media (Life Technologies) plus 10% FBS (Sigma). Human cervical cancer cell line HeLa (ATCC) was cultured in DMEM (Life Technologies) plus 10% FBS. All cells were cultured at 37°C and 5% CO2. JQ1 as described previously (30) was dissolved in DMSO (Corning) and added to media in treatment with JQ1. DMSO was replaced every 48 hours with fresh media to maintain the same concentrations. After 7 days of treatment, JQ1 was removed by spinning cells at 1,500 rpm for 5 minutes and replating cells in fresh media.

Analyses of cell viability, cell cycle, and apoptosis

To assess cell viability, cells were collected and resuspended in staining media: Hanks’ balanced salt solution (Life Technologies), 3% FBS, 0.2% sodium azide, 1 mmol/L EDTA, and 1 μg/mL propidium iodide (PI). Viable cell numbers were determined using a MACSQuant analyzer (Miltenyi Biotech). For cell-cycle analysis, cells were collected, resuspended in PBS, permeabilized, and fixed with 95% ice-cold ethanol overnight. PI was added before analyzing samples by flow cytometry using a FACSCalibur (BD biosciences). Flow cytometric data were analyzed using FlowJo software (Treestar). Apoptosis was analyzed using a caspase-GLO 3/7 kit with GloMax-96 microplate luminometer (Promega), following manufacturer’s recommendation.

Senescence-associated β-galactosidase staining

Whole-cell lysates were isolated using RIPA buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, and 0.02% sodium azide) plus fresh protease inhibitor complete (Roche). Lysates were run on SDS-PAGE Criterion X-gel (Bio-Rad) and transferred to nitrocellulose membranes (GE Osmonics). Membranes were probed with antibodies against BCL-XL, Rb (Cell Signaling Technology); c-MYC, p21, p53, β-actin (Santa Cruz Biotechnology); and p16 (Abcam). Membranes were visualized using Western lightening chemiluminescence detection (PerkinElmer) and ChemiDoc MP System with Image lab software (Bio-Rad).

Mouse studies

All mouse studies were carried out according to guidelines approved by the Institutional Animal Care and Use Committee of University of Massachusetts Medical School. Two- to 4-month-old male NOD.Cg-Prkd−/−Il2rg−/−SzJ (NSG) mice (Jackson Laboratory) were maintained on a biweekly regimen of antibiotic water (400 μg/mL of sulfamethoxazole and 80 μg/mL of trimethoprim oral suspension from HiTech Pharmacal). For tumor...
engraftment studies, 5 × 10^6 cells suspended in 50% Matrigel (BD Biosciences) were injected subcutaneously into the hind flank of each mouse (2 sites per mouse). Tumors were measured using a digital caliper 3 times weekly for 21 days or until sacrifice. Tumor volumes were calculated using a formula: \[ \frac{4}{3} \pi r_1r_2r_3 \] where \( r_1, r_2, \) and \( r_3 \) are the radii for three dimensions of tumor. For survival studies, 5 × 10^6 cells were injected intraperitoneally (i.p.). After detection of tumor by palpation (subcutaneously injected) or 6 days after tumor cell injection (intraperitoneally injected), tumor-bearing mice were randomized and treated with daily intraperitoneal injection of JQ1 (50 mg/kg of mouse body weight) for 21 days or until tumor volume reached 1,000 mm^3 or mice became moribund. JQ1 was first dissolved in DMSO and subsequently mixed with 10% hydroxypropyl-\( \beta \)-cyclodextrin (Sigma) to improve solubility. Vehicle-treated mice were injected with the equivalent volume of DMSO mixed with 10% hydroxypropyl-\( \beta \)-cyclodextrin. Tissues were harvested 2 hours after injection with JQ1 or vehicle in 10% neutral-buffered formalin for paraffin sections. Tissue sections were stained with hematoxylin and eosin (H&E).

Statistical analyses

Data were presented as mean ± SD. The Welch t test and 2-way ANOVA were used for statistical analyses, with \( P < 0.05 \) considered as statistically significant. Kaplan–Meier survival curves were plotted and analyzed with the log-rank test.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** JQ1 treatment of human DLBCL cell lines leads to decreased cell viability. A, twelve cell lines, including 11 human DLBCL cell lines and a human cervical cancer cell line HeLa, were treated with the indicated doses of JQ1 for 3 days. Viable cells were determined by PI exclusion in flow cytometry. The number of viable cells after JQ1 treatment is normalized as percent of viable cell number of DMSO-treated control. Error bars are SD of at least 3 independent experiments. B, proliferation of 4 DLBCL cell lines. Cells were treated with the indicated doses of JQ1 and doxorubicin (Dox), and viable cells were determined by PI exclusion in flow cytometry at indicated time after treatment. Error bars are SD of 3 independent experiments. Two-way ANOVA was used to compare JQ1 or doxorubicin-treated with DMSO-treated controls. ***: \( P < 0.001 \).
Figure 2. JQ1 induces cell-cycle arrest and cell death in human DLBCL cells. Cell-cycle analyses of DLBCL cells treated with JQ1 or doxorubicin (Dox) for 2 and 7 days were shown. Error bars are SD of 3 independent experiments. The Welch t test was used for statistical analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Results

Human DLBCL cells are sensitive to JQ1

Recent studies found antiproliferative and proapoptotic effects of JQ1, particularly in hematopoietic malignancies, and these effects of JQ1 are primarily mediated through inhibition of c-MYC (30, 33–40). Given recently reported incidence of c-MYC overexpression in DLBCL (28), we hypothesized that JQ1 treatment would inhibit human DLBCL cell proliferation and therefore might be effective in DLBCL therapy. To test this hypothesis, we used a panel of 11 human DLBCL cell lines, including 4 cell lines classified as the ABC subtype [HL-60 (ref. 17), HLY-1 (ref. 41), OCI-Ly3 and OCI-Ly10 (ref. 42)] and 7 cell lines classified as the GCB subtype [OCI-Ly8, OCI-Ly18, SU-DHL-4, SU-DHL-5, SU-DHL-6, SU-DHL-10 (ref. 41) and RC-K8 (ref. 27)].

We treated these 11 DLBCL cell lines with increasing doses of JQ1 for 3 days, at which time we determined the number of viable cells by PI exclusion and flow cytometry. As shown in Fig. 1A, total viable cells after JQ1 treatment as a percentage of DMSO-treated control cells (set to be 100%) were decreased significantly in a dose-dependent manner in all 11 DLBCL cell lines. The JQ1 dose that led to 50% inhibition of growth in DLBCL cell lines was between 25 and 160 nmol/L, compared with 360 nmol/L for the less sensitive human cervical cancer cell line HeLa (37). Both the ABC and GCB subtypes were sensitive to JQ1, suggesting a broad effect of JQ1 in inhibiting DLBCL cell proliferation. Furthermore, we treated 4 cell lines (ABC: OCI-Ly3; GCB: OCI-Ly8, SU-DHL-4 and SU-DHL-10) with 2 different doses of JQ1 (250 and 500 nmol/L) and determined the number of viable cells at 2, 3, 4, and 7 days after treatment. As shown in Fig. 1B, the numbers of viable cell at different time points after JQ1 treatment were significantly lower than those treated with the DMSO control, indicating an antiproliferative effect of JQ1 in DLBCL cells.

JQ1 treatment induces cell-cycle arrest in DLBCL cells followed by either apoptosis or senescence

In comparison to doxorubicin, which is known to induce apoptosis, the number of viable cells after JQ1 treatment decreased more slowly (Fig. 1B). To understand the mechanism underlying the antiproliferative effect of JQ1 in DLBCL cells, we analyzed cell-cycle distribution using flow cytometry at various time points after JQ1 treatment. After 2 days of JQ1 treatment, a significant decrease in percentage of cells in the S-phase and a significant increase in percentage of cells in the G1 phase of the cell cycle were observed (Fig. 2). Furthermore, there was insignificant or minimal increase in the sub-G1 population (Fig. 2), suggesting that JQ1 induces cell-cycle arrest with minimal cell death after 2 days of JQ1 treatment. After 4 days of JQ1 treatment, OCI-Ly8 and SU-DHL-4 cells maintained cell-cycle arrest, whereas a consistent increase in the sub-G1 population was observed in OCI-Ly3 (5.5% for 250 nmol/L JQ1-treated and 7.8% for 500 nmol/L JQ1-treated compared with 0.7% for DMSO-treated control) and SU-DHL-10 (3.1% for 250 nmol/L JQ1-treated and 3.5% for 500 nmol/L JQ1-treated compared with 1.1% for DMSO-treated control; Supplementary Fig. S1). In comparison, doxorubicin treatment led to a significant increase in the sub-G1 population in SU-DHL-10, OCI-Ly3, and OCI-Ly8 cells even after 2 days of treatment (Fig. 2 and Supplementary Fig. S1). Neither doxorubicin nor JQ1 induced a significant increase in the sub-G1 population in SU-DHL-4 cells up to 4 days of treatment (Fig. 2 and Supplementary Fig. S1). To further investigate cell death after JQ1 treatment, we measured caspase-3/7 activity as an indicator of apoptosis. We found a small but consistent increase in caspase-3/7 activity 4 days after treatment with 250 nmol/L JQ1 compared with DMSO-treated control cells in OCI-Ly3 (2.8-fold increase) and SU-DHL-10 (1.6-fold increase) cells, whereas a significant increase in caspase-3/7 activity was observed in both OCI-Ly3 (12.9-fold increase) and SU-DHL-10 (353-fold increase) cells after 4 days of doxorubicin treatment compared with DMSO-treated controls (Fig. 3A).

Interestingly, we found that the initial G1 cell-cycle arrest was followed by either apoptosis or senescence after longer (7-day) treatment with JQ1. OCI-Ly3, SU-DHL-4, and SU-DHL-10 cells showed significant increase in the sub-G1 populations: 27.5% (250 nmol/L JQ1) and 12.2% (500 nmol/L JQ1) compared with 1.0% (DMSO) for OCI-Ly3; 19.3% (250 nmol/L JQ1) and 31.6% (500 nmol/L JQ1) compared with 2.8% (DMSO) for SU-DHL-4; 9.2% (250 nmol/L JQ1) and 8.2% (500 nmol/L JQ1) compared with 2.3% (DMSO) for SU-DHL-10 cells (Fig. 2). In contrast, OCI-Ly8 did not have an increased sub-G1 population but rather maintained a G1 arrest (Fig. 2). Apoptosis in SU-DHL-4, SU-DHL-10, and OCI-Ly3 cells and the lack of cell death in OCI-Ly8 cells were corroborated by the analysis of caspase-3/7 activity. As shown

![Figure 3. JQ1 induces apoptosis in human DLBCL cells. Caspase-3/7 activity in DLBCL cells treated with JQ1 or doxorubicin (Dox) for (A) 4 days or (B) 7 days was measured and normalized with that in cells treated with DMSO, which was set to be 1. Error bars are SD of 5 independent experiments. The Welch t test was used for statistical analysis. ***, P < 0.001.](https://www.aacrjournals.org/doi/abs/10.1158/1078-0432.CCR-13-3346)
in Fig. 3B, a significant increase in caspase-3/7 activity was observed in SU-DHL-10, SU-DHL-4, and OCI-Ly3 cells treated with 250 nmol/L JQ1 compared with DMSO control (16-, 20-, and 6.2-fold increase, respectively). In comparison, OCI-Ly8 showed only a small increase (2.4-fold increase) in caspase-3/7 activity after 7 days of treatment with 250 nmol/L JQ1.

To further characterize the antiproliferative effects of JQ1, we removed JQ1 after 7 days of treatment and asked whether removal of the drug from the cells for an extended period allowed the cells to re-enter the cell cycle. All of the 4 cell lines tested either maintained growth arrest or in the case of SU-DHL-4 had decreased cell numbers (Fig. 4A). This suggests that JQ1 treatment caused cells to permanently exit the cell cycle. To test whether these cells entered senescence, we stained them for SA-β-gal activity. After 7 days of treatment with 250 nmol/L JQ1, we observed a significant percentage of cells staining positively for SA-β-gal in OCI-Ly3 (71.6%) and OCI-Ly8 (90.6%) cells. In contrast, only 5.4% or no SA-β-gal-positive cells were observed in SU-DHL-10 and SU-DHL-4 after JQ1 treatment for 7 days (Fig. 4B). These data indicate that JQ1 treatment results in 2 independent phenotypes in human DLBCL cell lines: apoptosis and senescence.

JQ1 treatment leads to suppression of c-MYC expression

As JQ1-mediated suppression of c-MYC expression is responsible for its antiproliferative effect in various types of cancer cells (33, 36, 43–45), we examined c-MYC protein levels in the 11 DLBCL cell lines that were characterized for response to JQ1 treatment. In particular, OCI-Ly3 (46) and SU-DHL-4 (47) cells have c-MYC amplifications. HBL-1 (48), OCI-Ly8, OCI-Ly18 (46), SU-DHL-6, and SU-DHL-10 (47) cells have c-MYC translocations, whereas c-MYC loci in RC-K8 (49), SU-DHL-5 (47), OCI-Ly10, and HLY-1 (John Manis, personal communication) cells are normal. We found that these cell lines expressed varying amounts of c-MYC protein (Fig. 5A). After JQ1 treatment for 2 days, c-MYC protein level was clearly decreased in 10 of 11 DLBCL cell lines that we tested (Fig. 5A). The c-MYC level did not change significantly in SU-DHL-10 cells after 2 days of JQ1 treatment (Fig. 5A). However, an 88% decrease in the c-MYC protein level was observed in SU-DHL-10 cells after 7 days of JQ1 treatment.
JQ1 treatment decreased the c-MYC level in cells with c-MYC translocations (HBL-1, OCI-Ly8, OCI-Ly18, SU-DHL-6, and SU-DHL-10), c-MYC amplifications (OCI-Ly3 and SU-DHL-4) or without change in the c-MYC loci (RC-K8, SU-DHL-5, OCI-Ly10, and HLY-1). These data suggest that JQ1-mediated suppression of c-MYC can occur at the natural, chromosomally translocated, or gene-amplified c-MYC loci.

To understand the possible mechanisms of the apoptosis versus senescence response after JQ1 treatment, we examined expression of proteins previously implicated in these processes. Levels of antiapoptotic factor BCL-XL either did not change or decreased upon JQ1 treatment (Fig. 5B). In addition, proteins known to regulate senescence, p16, p21, and Rb, were either undetectable or showed decreased expression after JQ1 treatment. Protein levels of p53 were not changed and its mutation status did not appear to correlate with response to JQ1 treatment, as OCI-Ly3 cells have wild-type p53 (50) and OCI-Ly8 cells harbor a mutated p53 (46). Although p53 in SU-DHL-10 and SU-DHL-4 cells has not been annotated, the reduced p53 protein size in SU-DHL-10 suggests a truncation (Fig. 5B).

JQ1 treatment of xenograft tumors results in significantly decreased rate of tumor growth and increased survival of mice

To evaluate how DLBCL cells xenografted into NSG mice would respond to a regimen of treatment with JQ1, we began by engrafting OCI-Ly8 cells subcutaneously into NSG mice. When at least one tumor on each mouse was detectable by palpation, we began a daily treatment of JQ1 (50 mg/kg of mouse body weight) or vehicle for 21 days. Seven mice from the vehicle-treated group and 4 mice from JQ1-treated group had to be euthanized before the end of treatment regimen because tumor volumes reached 1,000 mm³. Tumor growth was significantly decreased in JQ1-treated mice compared with vehicle-treated mice (P < 0.001; Fig. 6A). In addition to subcutaneously injected tumors, we used OCI-Ly8 cells to engraft NSG mice intraperitoneally to better mimic human disease. Six days after cell injection, we began daily treatment with 50 mg/kg JQ1 or vehicle for 21 days. After the completion of treatment, we monitored the mice until all were moribund and therefore had to be euthanized. JQ1 significantly (P = 0.0039) increased survival time with a mean survival of 33.6 days compared with 29.5 days for vehicle (Fig. 6B). Upon sacrifice, mice displayed infiltration of tumor cells into spleen and liver (Fig. 6C) as well as prominent abdominal masses.

Discussion

In this study, we demonstrated that targeting BRD proteins by JQ1 in human DLBCL cells resulted in cell death or cell senescence. We found that DLBCL cells were sensitive to JQ1 treatment regardless of molecular subtypes (ABC vs. GCB), suggesting that
JQ1 has a broad effect in DLBCL. This broad effect is especially encouraging for the potential clinical use of JQ1 for DLBCL treatment. Recent studies have found antiproliferative and proapoptotic effects of JQ1, particularly in hematopoietic malignancies, and these effects of JQ1 are primarily mediated through inhibition of c-MYC [30, 33–40]. Consistent with these findings, we showed that JQ1 mediated suppression of c-MYC expression, regardless of whether it is from unperturbed c-MYC loci (HLY-1, OCI-Ly10, RC-K8, and SU-DHL-5) or from chromosomally translocated (HL-1, OCI-Ly8, OCI-Ly18, SU-DHL-6, and SU-DHL-10) or amplified (OCI-Ly3 and SU-DHL-4) loci. Collectively, our studies suggest that inhibition of c-MYC via BET bromodomain family proteins by JQ1 provides a promising therapeutic model for patients with DLBCL.

Previously, it has been shown that cancer cells respond to JQ1 primarily with rapid cell-cycle arrest and apoptosis [30, 33–35, 37, 38]. These studies demonstrate increased apoptotic markers within 2 to 3 days of JQ1 treatment. We found 2 distinct phenotypes in response to JQ1: senescence or apoptosis. OCI-Ly8 cells displayed G1 arrest and positive staining for SA-beta-gal without increases in sub-G1 population and apoptosis following JQ1 treatment, indicating that senescence is the main response to JQ1 in OCI-Ly8 cells. SU-DHL-4 and SU-DHL-10 cells showed little or no positive SA-beta-gal staining but increased sub-G1 population and apoptosis, indicating that apoptosis is the prominent response to JQ1 in these 2 cell lines. Both apoptosis and senescence were observed in OCI-Ly3 cells. The apoptosis versus senescence phenotype did not correlate with the parameters that we examined, including molecular subtype (ABC: OCI-Ly3 vs. GCB: OCI-Ly8 and SU-DHL-10), p53 mutation status (wild-type: OCI-Ly3 vs. mutated: OCI-Ly8 and SU-DHL-10), c-MYC translocation and expression level (amplified: OCI-Ly3...
JQ1 for Treatment of Diffuse Large B-cell Lymphoma

and SU-DHL-4; translocated: SU-DHL-10 and OCI-Ly8). BCL2 translocation status [translocated: SU-DHL-4, SU-DHL-10 (ref. 47) and OCI-Ly8 (ref. 46), amplified: OCI-Ly3 (ref. 46)], or expression of p16, p21, p53, Rh, or BCL-XL. A recent study revealed highly asymmetric loading of BRD4 at superenhancers in DLBCL cells. These superenhancers and genes that they regulate are particularly sensitive to JQ1 inhibition, explaining the selective effect of JQ1 on oncogenic and lineage-specific transcriptional circuits (32). It will be interesting to understand how this selectivity of BRD4 loading at superenhancers and inhibition by JQ1 are responsible for the different responses (apoptosis vs. senescence) to JQ1 in DLBCL cells.

We showed that JQ1 significantly suppressed growth of DLBCL cells engrafted in NSG mice and improved survival of tumor-bearing mice, demonstrating a potential use of JQ1 in DLBCL treatment. We found that JQ1 alone with the regimen tested was not sufficient to cure the disease. The differences in JQ1 effectiveness observed between in vitro and in vivo studies could be due to a number of issues, one of which is bioavailability in vivo. The half-life of JQ1 in plasma is relatively low: 0.9 hours (intravenous injection of 5 mg/kg) or 1.4 hours (oral administration of 10 mg/kg; ref. 30). When dosed every 24 hours, it is likely that very little JQ1 remains after 8 hours. Although it has not been previously measured, the effective concentration of JQ1 at the site of tumors is likely even lower than in the plasma, because the typically poor vasculature in tumor tissues could prevent JQ1 from being effectively delivered to the tumor cells. A recent study using 2 daily doses of JQ1 treatment for 30 days (vs. 1 daily dose for 21 days in our study) shows a median survival advantage of 9 days in NSG mice with DLBCL xenografts (32) compared with 4 days in our study, suggesting that more frequent dosing to maintain plasma concentration of JQ1 over time may increase its effectiveness in vivo, especially given that no adverse effects have been reported for JQ1 use in mouse models. Additional modifications to the structure of JQ1 that maintain its specificity while increasing the half-life will make JQ1 more effective in vivo and in clinical use.

It is possible to combine the use of JQ1 with the current standard therapy to increase the efficacy of treatment. A recent study by Emadali and colleagues showed that the addition of JQ1 to rituximab increases sensitivity of rituximab-resistant DLBCL to current treatments may be beneficial. Another study has demonstrated additional value of JQ1 in combination with other novel therapies for DLBCL. Zhao and colleagues show that treating DLBCL cell lines with EZH2 inhibitor DZNep and JQ1 reduces cell viability in a synergistic manner (40). We propose that JQ1 should be examined clinically in patients with DLBCL. We speculate that the addition of JQ1 as a component of salvage therapy or even potentially added to R-CHOP therapy may result in the effective treatment of DLBCL. Continued examination of JQ1 alone and in combination with other novel therapeutic agents is warranted.

Disclosure of Potential Conflicts of Interest

J.E. Bradner has ownership interest (including patents) in and is a consultant/advisory board member for Tenshia Therapeutics. D.L. Greiner is a consultant/advisory board member for The Jackson Laboratory. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S.E. Trabucco, R.M. Gerstein, D.L. Greiner, H. Zhang

Development of methodology: S.E. Trabucco, R.M. Gerstein, D.L. Greiner, H. Zhang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.E. Trabucco, R.M. Gerstein, D.L. Greiner

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.E. Trabucco, R.M. Gerstein, A.M. Evens, J.E. Bradner, D.L. Greiner, H. Zhang

Writing, review, and/or revision of the manuscript: S.E. Trabucco, R.M. Gerstein, A.M. Evens, J.E. Bradner, D.L. Shultz, D.L. Greiner, H. Zhang

Study supervision: R.M. Gerstein, H. Zhang

Acknowledgments

The authors thank Drs. Subbarama Bondada, John Manis, and Louis Staudt for kindly providing reagents.

Grant Support

This work was supported by NIH research grants AI046629 (D.L. Greiner and L.D. Shultz), CA034196 (L.D. Shultz), and CA131210 (H. Zhang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 11, 2013; revised May 29, 2014; accepted June 20, 2014; published OnlineFirst July 9, 2014.

References


32. Ballesta J, Johnson NG, Weksberg R. BET bromodomain protein inhibition is a therapeutic option for medioloblas-


Clinical Cancer Research

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma

Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-3346

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/07/14/1078-0432.CCR-13-3346.DC1
http://clincancerres.aacrjournals.org/content/suppl/2014/07/18/1078-0432.CCR-13-3346.DC2

Cited articles
This article cites 50 articles, 19 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/1/113.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/21/1/113.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.